Scientists have developed a tool that can predict how bowel cancer adapts to treatment – helping researchers to design new ...

Scientists have developed a tool that can predict how bowel cancer adapts to treatment—helping researchers to design new ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

New research shows that treatment timing is key when it comes to deciding between immunotherapy and chemoimmunotherapy for ...

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

The venom of a common species of Amazonian scorpion may give rise to a potential drug for treating a cancer that is one of ...

A chemotherapy-free approach for some patients suffering from leukaemia could lead to better outcomes, scientists behind a ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The exercise prescriptions also prevented other new cancers, like breast and prostate cancer. Many included just three to ...

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...